advertisement
Abstract #98266 Published in IGR 22-4
Diagnosis and Management of Idiopathic Persistent Iritis after Cataract Surgery (IPICS)
Soifer M; Soifer M; Mousa HM; Jammal AA; Savarain C; Perez VLAmerican Journal of Ophthalmology 2022; 234: 250-258
PURPOSE: To investigate the diagnosis and management of patients with idiopathic persistent iritis after cataract surgery (IPICS). DESIGN: Retrospective interventional case series. METHODS: Patients diagnosed with IPICS were evaluated for demographic and clinical characteristics and immune blood markers. Those with more than 6 months of follow-up were evaluated for treatment efficacy to achieve remission (ie, absence of inflammation for 3 months), with either exclusive slow tapering of topical steroids or the need for systemic immunosuppression. RESULTS: Forty-five patients presented with IPICS. Most were African American (39, 86.7%) or female (33, 77.3%). Antinuclear antibodies were present in 23 (69.9%) of patients. Main complications were steroid dependency (38,84.4%), glaucoma (24,53.5%), and macular edema (11,37.5%). Thirty two patients presented treatment follow up. On these,the proposed treatment strategy achieved remission in 30 (93.8%) of cases in a mean of 6.1 months via tapering of topical steroids in 15 (46.9%) of patients. However, in 17 (53.1%) of cases, adjuvant anti-inflammatory systemic medication was indicated. Meloxicam use was associated with remission in 11 (64.7%) of these patients and, in a minority with persistent iritis, treatment was escalated to methotrexate, which was successful in 4 (100%) of the cases. CONCLUSIONS: IPICS is a distinct clinical anterior uveitis most common in African American and female patients, characterized by an unexpected onset of iritis after cataract surgery and high rates of steroid dependency, glaucoma, and macular edema. It is best treated with an initial slow taper of topical steroids; although adjuvant systemic anti-inflammatory therapy may be necessary to obtain remission and avoid complications.
Foster Center for Ocular Immunology, Duke Eye Institute, Durham, North Carolina, USA (M.S., H.M.M., C.S., V.L.P.); and Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, USA (M.S., H.M.M., A.A.J., C.S., V.L.P.).
Full article